PO11 | Neutrophil cathepsin G and risk of cardiovascular events in patients with diabetes mellitus
V. Cammisotto1, F. Baratta2, S. Bartimoccia3, D. Pastori1, N. Cocomello4, V. Castellani5, C. Nocella1, R. Carnevale3, G. Desideri1, F. Violi1, P. Pignatelli1 | 1Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma; 2Geriatric Unit, Department of Internal Medicine and Medical Specialties, AOU Policlinico Umberto I, Roma; 3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma; 4Department of Anatomical Sciences, Histological, Legal Medical and Locomotor, Sapienza University of Roma; 5Department of Experimental Medicine, Sapienza University of Roma, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background and Aims: Type 2 diabetes mellitus (T2DM) is a major risk factor for atherosclerosis and cardiovascular events (CVEs), partly due to increased platelet activation and inflammation. Neutrophil-derived cathepsin G (CatG), a prothrombotic protease, may play a role in this process by promoting platelet aggregation. However, its association with CVEs in T2DM has not been previously explored. This study aimed to evaluate whether circulating CatG levels independently predict CVEs in patients with T2DM.
Methods: We included 485 T2DM patients from two prospective cohorts (PLINIO and ATHERO-AF). The primary outcome was a composite of cardiovascular death, non-fatal coronary and cerebrovascular events, and peripheral artery events. Multivariate Cox-regression was used to assess associations between CatG (≥ 3.06 ng/mL) and outcomes. A subgroup analysis was conducted in 302 patients with available neutrophil count data.
Results: During the follow-up yielding for 2,437.6 person-years, 86 CVEs occurred. Patients developing CVEs ha higher catG (2.9 [1.9–4.4] ng/mL vs. 2.1 [1.6–2.6] ng/mL; p <0.001) compared to CVEs-free patients. CatG ≥ 3.06 ng/mL levels were significantly associated with increased CVEs risk (adjusted Hazard Ratio (aHR) 7.203, p<0.001), and with secondary outcomes including cardiovascular mortality or non-fatal coronary events or all-cause mortality: this association with CVEs remained significant after adjustment for neutrophil count (aHR 5.301, p<0.001). Neutrophil count was also independently associated with CVEs (aHR 1.173, p=0.042).
Conclusions: Circulating CatG is an independent predictor of cardiovascular events in T2DM, suggesting a novel biomarker linking inflammation with athero-thrombosis.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
